We are pleased to announce that PathologyAI has closed a €24M Series A financing round. The round was led by a specialist European health-tech fund, with participation from our seed investors and two strategic partners from the diagnostics industry.
Where the capital goes
The funding is allocated against three priorities that directly serve our clinical partners. First, completing our CE IVDR submissions across the breast and gastrointestinal indications. Second, expanding our clinical deployment team so that every partner site is paired with a dedicated implementation lead. Third, continuing to invest in foundation models for histology, with a focus on fairness, calibration, and reliable behaviour in low-prevalence subpopulations.
This is operating capital, not marketing capital. Our commitment to partners is simple: every euro we raise should make the platform safer, faster, or more useful inside their laboratory.
What stays the same
Our geographic focus remains Europe. Our clinical-first philosophy remains unchanged. And our data governance position — that patient data stays inside the institution of origin — is now a formal commitment written into our investor agreements.
